About relay therapeutics inc - RLAY
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
RLAY At a Glance
Relay Therapeutics, Inc.
60 Hampshire Street
Cambridge, Massachusetts 02139
| Phone | 1-617-370-8837 | Revenue | 15.36M | |
| Industry | Biotechnology | Net Income | -276,479,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 53.443% | |
| Fiscal Year-end | 12 / 2026 | Employees | 192 | |
| View SEC Filings |
RLAY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 94.537 |
| Price to Book Ratio | 2.594 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.107 |
| Enterprise Value to Sales | 60.538 |
| Total Debt to Enterprise Value | 0.035 |
RLAY Efficiency
| Revenue/Employee | 79,973.958 |
| Income Per Employee | -1,439,994.792 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.021 |
RLAY Liquidity
| Current Ratio | 22.608 |
| Quick Ratio | 22.608 |
| Cash Ratio | 21.679 |
RLAY Profitability
| Gross Margin | 76.835 |
| Operating Margin | -1,971.592 |
| Pretax Margin | -1,800.58 |
| Net Margin | -1,800.58 |
| Return on Assets | -37.046 |
| Return on Equity | -41.117 |
| Return on Total Capital | -46.117 |
| Return on Invested Capital | -39.042 |
RLAY Capital Structure
| Total Debt to Total Equity | 5.724 |
| Total Debt to Total Capital | 5.414 |
| Total Debt to Total Assets | 5.224 |
| Long-Term Debt to Equity | 5.06 |
| Long-Term Debt to Total Capital | 4.786 |